Preoperative breast MR imaging in newly diagnosed breast cancer: Comparison of outcomes based on mammographic modality, breast density and breast parenchymal enhancement.


Journal

Clinical imaging
ISSN: 1873-4499
Titre abrégé: Clin Imaging
Pays: United States
ID NLM: 8911831

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 08 05 2020
revised: 26 09 2020
accepted: 07 10 2020
pubmed: 30 10 2020
medline: 27 1 2021
entrez: 29 10 2020
Statut: ppublish

Résumé

To compare the role of MR for assessment of extent of disease in women newly diagnosed with breast cancer imaged with digital mammography (DM) alone versus digital breast tomosynthesis (DBT). Retrospective review was conducted of 401 consecutive breast MR exams (10/1/2013-7/31/2015) from women who underwent preoperative MR for newly diagnosed breast cancer by either DM or DBT, leaving 388 exams (201 DM and 187 DBT). MR detection of additional, otherwise occult, disease was stratified by modality, breast density, and background parenchymal enhancement. A true-positive finding was defined as malignancy in the ipsilateral-breast >2 cm away from the index-lesion or in the contralateral breast. 50 additional malignancies were detected in 388 exams (12.9%), 37 ipsilateral and 13 contralateral. There was no difference in the MR detection of additional disease in women imaged by either DM versus DBT (p = 0.53). In patients with DM, there was no significant difference in the rate of MR additional cancer detection in dense versus non-dense breasts (p = 0.790). However, in patients with DBT, MR detected significantly more additional sites of malignancy in dense compared to non-dense breasts (p = 0.017). There was no difference in false-positive MR exams (p = 0.470) for DM versus DBT. For both DM and DBT cohorts, higher MR background parenchymal enhancement was associated with higher false-positive (p = 0.040) but no significant difference in true-positive exams. Among patients with DBT imaging at cancer diagnosis, women with dense breasts appear to benefit more from preoperative MR than non-dense women. In women imaged only with DM, MR finds additional malignancy across all breast densities.

Identifiants

pubmed: 33120285
pii: S0899-7071(20)30385-5
doi: 10.1016/j.clinimag.2020.10.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-24

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016520
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Azadeh Elmi (A)

Breast Imaging Division, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.

Emily F Conant (EF)

Breast Imaging Division, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: Emily.conant@uphs.upenn.edu.

Andrew Kozlov (A)

Breast Imaging Division, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: Andrew.kozlov@uphs.upenn.edu.

Anthony J Young (AJ)

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: Anthony.Young@pennmedicine.upenn.edu.

Qi Long (Q)

Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: qlong@pennmedicine.upenn.edu.

Robert K Doot (RK)

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: robdoot@pennmedicine.upenn.edu.

Elizabeth S McDonald (ES)

Breast Imaging Division, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: elizabeth.mcdonald@pennmedicine.upenn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH